oral glp-1 weight loss The First Pill for Is Here. Is It as Good as the Injection? No nausea FDA Approves First Oral GLP-1

Differential pathophysiological mechanisms between CHS and EHS While CHS and EHS share core pathogenic pathways (e.g., hyperthermia, inflammation, cell death), their mechanistic features differ significantly due to distinct patient demographics and triggers: Inflammatory kinetics EHS (predominant in young, active individuals) is characterized by rapid, exertion-amplified inflammatory responses

[PubMed: 10670734] 111

Superoxide dismutase (SOD) and glutathione peroxidase (GP) activity in erythrocytes are involved in the psoriasis onset (7)

Br J Pharmacol 94:413422 Foster AC, Kemp JA (2006) Glutamate- and GABA-based CNS therapeutics

In 2023, the market was valued at approximately US $3.6 billion, and it is projected to reach $6.2 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 8% during the forecast period (20242030) [8]